Leber Congenital Amaurosis Clinical Trial
Official title:
A Phase 1/2 Dose Escalation Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D
Primary Objective: To evaluate the safety and tolerability of ascending doses of ATSN-101 administered as a unilateral subretinal injection in patients with Leber Congenital Amaurosis (LCA) caused by autosomal recessive guanylate cyclase 2D (GUCY2D) mutations (GUCY2D-LCA). Secondary Objective: To evaluate the efficacy of ascending doses of ATSN-101 administered as a unilateral subretinal injection in patients with GUCY2D-LCA.
Study duration per participant is approximately 112 weeks including: an approximately 56-day screening/baseline period, an approximately 52-week study observation period including 1 treatment day, and an approximately 52-week safety follow-up period. The end of study visit will be approximately 260 weeks after the Investigational Medicinal Product (IMP) administration. After completion of the main study (ATSN-101-1), participants may have the option to enroll in a separate long-term follow-up study, in which case they would no longer continue in ATSN-101-1 and their end of study visit would be conducted at Week 52. The study is separated into 2 parts including a dose escalation phase (Part A) and a dose expansion phase (Part B). In Part B participants will be treated at the maximum tolerated dose (MTD) or maximum administered dose (MAD) determined from Part A. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01496040 -
Clinical Gene Therapy Protocol for the Treatment of Retinal Dystrophy Caused by Defects in RPE65
|
Phase 1/Phase 2 | |
Completed |
NCT02970266 -
Genetic Decryption of Leber Congenital Amaurosis (LCA) in a Large Cohort of Independent Families.
|
N/A | |
Completed |
NCT00516477 -
Safety Study in Subjects With Leber Congenital Amaurosis
|
Phase 1 | |
Recruiting |
NCT05906953 -
Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00999609 -
Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis
|
Phase 3 | |
Active, not recruiting |
NCT01208389 -
Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2
|
Phase 1/Phase 2 | |
Terminated |
NCT03913130 -
Extension Study to Study PQ-110-001 (NCT03140969)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04855045 -
An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene.
|
Phase 2/Phase 3 | |
Recruiting |
NCT02435940 -
Inherited Retinal Degenerative Disease Registry
|
||
Completed |
NCT00749957 -
Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
Not yet recruiting |
NCT04731883 -
RPE65 Gene Therapy (LX101)for Leber's Congenital Amaurosis
|
N/A | |
Recruiting |
NCT05203939 -
Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT06088992 -
Leber Congenital Amaurosis Inherited Blindness of Gene Therapy Trial(LIGHT)
|
Early Phase 1 | |
Recruiting |
NCT06064565 -
Leber Congenital Amaurosis Inherited Blindness of Gene Therapy Trial (LIGHT)
|
Early Phase 1 | |
Completed |
NCT00821340 -
Clinical Trial of Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations
|
Phase 1 | |
Active, not recruiting |
NCT03913143 -
A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)
|
Phase 2/Phase 3 | |
Completed |
NCT02714816 -
Natural History Study of Patients With Leber Congenital Amaurosis Associated With Mutations in RPE65
|
||
Completed |
NCT02781480 -
Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA)
|
Phase 1/Phase 2 |